Cytokeratin expression patterns in low‐grade papillary urothelial neoplasms of the urinary bladder
- 15 April 2003
- Vol. 97 (8) , 1876-1883
- https://doi.org/10.1002/cncr.11265
Abstract
BACKGROUND The differential expression patterns of cytokeratin 20 (CK20) and 34βE12 antigen in low‐grade papillary urothelial tumors of the bladder are discussed. METHODS A retrospective study of 120 patients with low‐grade papillary bladder tumors (45 neoplasms of low malignant potential and 75 low‐grade WHO G1 carcinomas) was performed. All tumors were graded in accordance with the 1998 World Health Organization/International Society of Urological Pathology (WHO/ISUP) and 1999 WHO classifications. The mean follow‐up was 76.6 months (range, 36–168 mos), considering for prognostic purposes the time to first recurrence, or relapse‐free interval (RFI), and the total number of recurrent patients. Immunohistochemically, normal or abnormal CK20 and 34βE12 antigen expression patterns were determined for each patient. CK20 (clone IT‐Ks) and a high‐molecular weight cytokeratin (clone 34βE12) were the monoclonal antibodies used in the immunohistochemical study. RESULTS Seventy‐seven of 120 patients (64.2%) experienced a recurrence during follow‐up. In recurrence prediction, the differential expression pattern of both cytokeratins showed a high sensitivity (76.6% for CK20 and 80.5% for 34βE12 antigen) and a high positive predictive value (85.5% for CK20 and 75.6% for 34βE12 antigen), although specificity was higher for CK20 (76.7%) than it was for 34βE12 antigen (53.4%). Independent of adjuvant intravesical chemotherapy, these 2 markers showed a strong statistical correlation (p < 0.001) in univariate studies with both the prediction of disease recurrences and RFI. CONCLUSIONS CK20 and 34βE12 antigen have proved to be strong predictive markers of disease recurrences when considering different topographic expression profiles, and, in the authors' opinion, these profiles could be incorporated into follow‐up clinicopathologic strategies. Cancer 2003;97:1876–83. © 2003 American Cancer Society. DOI 10.1002/cncr.11265Keywords
This publication has 14 references indexed in Scilit:
- Comparison of the WHO/ISUP Classification and Cytokeratin 20 Expression in Predicting the Behavior of Low-Grade Papillary Urothelial TumorsLaboratory Investigation, 2001
- Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial NeoplasiaLaboratory Investigation, 2000
- Assessment of basal cell status andproliferative patterns in flat and papillary urothelial lesions: A contribution to the new who classification of urothelial tumors of the urinary bladderHuman Pathology, 2000
- Cancer heterogeneity and its biologic implications in the grading of urothelial carcinomaCancer, 2000
- LONG-TERM FOLLOWUP OF INITIAL Ta GRADE 1 TRANSITIONAL CELL CARCINOMA OF THE BLADDERPublished by Wolters Kluwer Health ,1999
- Expression of cytokeratin 20 redefines urothelial papillomas of the bladderThe Lancet, 1999
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderThe American Journal of Surgical Pathology, 1998
- Cytokeratin 20 as an objective marker of urothelial dysplasiaBritish Journal of Urology, 1996
- Cytokeratin 20 expression by non‐invasive transitional cell carcinomas: potential for distinguishing recurrent from non‐recurrent diseaseHistopathology, 1995
- The Relationship Among Multiple Recurrences, Progression and Prognosis of Patients with Stages TA and T1 Transitional Cell Cancer of the Bladder Followed for at least 20 yearsJournal of Urology, 1995